Addex Therapeutics Liabilities 2024

Addex Therapeutics Aktienanalyse

What does Addex Therapeutics do?

Addex Therapeutics Ltd is a biotechnology company focused on the discovery and development of novel oral drugs. The company was founded in Geneva, Switzerland in 2002 and has made significant progress in researching drug candidates for various conditions such as schizophrenia, ADHD, migraines, and other central nervous system disorders. Addex Therapeutics' business model is based on the development of modulating therapeutics that specifically influence cellular signaling pathways. The company utilizes the proven AMC platform (Addex Modulation Cloning) to quickly and efficiently identify and validate specific receptor projects. Additionally, the company has a wide range of research and development programs, from preclinical to clinical study phases. Addex Therapeutics Ltd specializes in three therapeutic areas: neurological, immunological, and anti-inflammatory diseases. Within these areas, the company develops various drugs that specifically target certain receptors and provide help and relief for various conditions. One of Addex's most significant medical projects currently is the ADX71149 drug candidate for the treatment of schizophrenia and autism. Addex Therapeutics Ltd's products include a variety of neuromodulators and other drug candidates. The company has filed numerous international patents and maintains a high standard in the pharmaceutical development industry. The key product candidates are: - ADX10059: A new drug used in the treatment of migraines and dizziness. ADX10059 is a P2X3 receptor antagonist that can help suppress the transmission of pain signals in the central nervous system. - ADX88178: A drug candidate targeting the GABA-B receptor. This receptor is central to deep-seated pain and extrapyramidal side effects of classic antipsychotics. - ADX71943: A drug candidate used in the treatment of neuropsychiatric disorders such as Rett syndrome and ADHD. ADX71943 is a selective agonist of the GABA-B receptor, modulating the release of neurotransmitters in the brain. Overall, Addex Therapeutics offers an extensive product range and carries out a variety of projects in different stages of development. The company's core competency lies in modulators that can control specific receptors (neurotransmitter or hormone receptors). Addex Therapeutics Ltd is headquartered in Geneva, Switzerland, but also has branches in New York and San Francisco. The company focuses on expanding its competitiveness in the field of novel drugs and expanding its portfolio of products and international customers. Addex Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Addex Therapeutics's Liabilities

Addex Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Addex Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Addex Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Addex Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Addex Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Addex Therapeutics stock

What is the level of liabilities of Addex Therapeutics this year?

Addex Therapeutics has a debt balance of 0 CHF this year.

What were the liabilities of Addex Therapeutics compared to the previous year?

The liabilities of Addex Therapeutics have increased by -100% dropped compared to the previous year.

What are the consequences of high debt for investors of Addex Therapeutics?

High liabilities can pose a risk for investors of Addex Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Addex Therapeutics?

Low liabilities mean that Addex Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Addex Therapeutics affect the company?

An increase in liabilities of Addex Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Addex Therapeutics affect the company?

A decrease in the liabilities of Addex Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Addex Therapeutics?

Some factors that can influence the liabilities of Addex Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Addex Therapeutics so important for investors?

The liabilities of Addex Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Addex Therapeutics take to modify the liabilities?

To change its liabilities, Addex Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Addex Therapeutics pay?

Over the past 12 months, Addex Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Addex Therapeutics is expected to pay a dividend of 0 CHF.

What is the dividend yield of Addex Therapeutics?

The current dividend yield of Addex Therapeutics is .

When does Addex Therapeutics pay dividends?

Addex Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Addex Therapeutics?

Addex Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Addex Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Addex Therapeutics located?

Addex Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Addex Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Addex Therapeutics from 9/11/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 9/11/2024.

When did Addex Therapeutics pay the last dividend?

The last dividend was paid out on 9/11/2024.

What was the dividend of Addex Therapeutics in the year 2023?

In the year 2023, Addex Therapeutics distributed 0 CHF as dividends.

In which currency does Addex Therapeutics pay out the dividend?

The dividends of Addex Therapeutics are distributed in CHF.